Cargando…

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

BACKGROUND: Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. PATIENTS AND METHODS: Multicenter, observational, retrospective study in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puente, Javier, Laínez, Nuria, Dueñas, Marta, Méndez-Vidal, María José, Esteban, Emilio, Castellano, Daniel, Martinez-Fernández, Mónica, Basterretxea, Laura, Juan-Fita, María José, Antón, Luis, León, Luis, Lambea, Julio, Pérez-Valderrama, Begoña, Vázquez, Sergio, Suarez, Cristina, del Muro, Xavier Garcia, Gallardo, Enrique, Maroto, José Pablo, Samaniego, M Luz, Suárez-Paniagua, Beatriz, Sanz, Julián, Paramio, Jesús M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444752/ https://www.ncbi.nlm.nih.gov/pubmed/28423742 http://dx.doi.org/10.18632/oncotarget.16494

Ejemplares similares

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
por: Méndez-Vidal, María José, et al.
Publicado: (2023)

Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma
por: Prior, Celia, et al.
Publicado: (2014)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
por: Maroto, P, et al.
Publicado: (2017)

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
por: Cebrián, Arancha, et al.
Publicado: (2017)

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
por: Puente, Javier, et al.
Publicado: (2020)

SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
por: González del Alba, A., et al.
Publicado: (2018)

A Case of Metastatic Adamantinoma That Responded Well to Sunitinib
por: Liman, Andrew D., et al.
Publicado: (2016)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
por: Grünwald, Viktor, et al.
Publicado: (2023)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC)
por: Armesto, María, et al.
Publicado: (2021)

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
por: Lainez, Nuria, et al.
Publicado: (2016)

Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report
por: JURADO, JOSÉ MIGUEL, et al.
Publicado: (2013)

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
por: Stewart, Grant D., et al.
Publicado: (2016)

Design and Evaluation of a Scalable and Reconfigurable Multi-Platform System for Acoustic Imaging
por: Izquierdo, Alberto, et al.
Publicado: (2016)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma
por: Nagase, Kei, et al.
Publicado: (2021)

Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma
por: Font, Albert, et al.
Publicado: (2021)

Combined Papillated Bowen Disease and Clear Cell Atypical Fibroxanthoma
por: Suárez-Vilela, Dimas, et al.
Publicado: (2010)

HelpResponder—System for the Security of First Responder Interventions
por: Rodriguez-Sanchez, M. Cristina, et al.
Publicado: (2021)

(Un)Broken: Lateral violence among hospital nurses, user violence, burnout, and general health: A structural equation modeling analysis
por: Vidal-Alves, Maria Joao, et al.
Publicado: (2022)

Metastatic Thymic Carcinoma with Long Survival After Treatment with Sunitinib
por: Cabezón-Gutiérrez, Luis, et al.
Publicado: (2018)

Advances in integrated and sustainable supply chain planning: concepts, methods, tools and solution approaches toward a platform for industrial practice
por: Laínez-Aguirre, José Miguel, et al.
Publicado: (2015)

El mundo de Santa
por: Suárez, José Luis M. (José Luis Martínez), 1958-

Santa, de Federico Gamboa: una lectura social/
por: Suárez, José Luis M. (José Luis Martínez), 1958-
Publicado: (2003)

Intima patria : ensayo
por: Suárez, José Luis M. (José Luis Martínez), 1958-

Distancia de ti
por: Suárez, José Luis M. (José Luis Martínez), 1958-

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
por: Kontovinis, Loukas F, et al.
Publicado: (2009)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases
por: Furubayashi, Nobuki, et al.
Publicado: (2014)

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
por: Pilskog, Martin, et al.
Publicado: (2017)

Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma
por: Peng, Qiang, et al.
Publicado: (2019)

TFE3‐PD‐L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma
por: Guo, Xudong, et al.
Publicado: (2020)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Wei, Yuang, et al.
Publicado: (2021)

Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma
por: Song, Zhengshuai, et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
por: Eto, Masatoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_01bpsallrvr3ucubvk9eclth9o